JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $174
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma and raises the price target from $170 to $174.
August 21, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has reaffirmed its Overweight rating on Ascendis Pharma and increased the price target from $170 to $174, indicating a positive outlook.
The increase in price target from $170 to $174 by JP Morgan suggests a positive outlook for Ascendis Pharma, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100